BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
BrainStorm Cell Therapeutics appointed Peter J. Pitts, former FDA Associate Commissioner, to its Board of Directors effective immediately. The appointment coincides with the company's preparation to initiate a Phase 3b ENDURANCE trial for its lead ALS therapy, NurOwn, under a Special Protocol Assessment (SPA) with the FDA.
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.